Actively Recruiting
Phase II Study Comparing Morning Versus Later Day Immunotherapy with Ipilimumab and Nivolumab for Advanced or Unresectable Melanoma
Led by Emory University · Updated on 2025-11-12
99
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying advanced melanoma that is stage IV or cannot be removed by surgery to see if giving immunotherapy drugs ipilimumab and nivolumab at different times of the day affects how well they work. These drugs help the bodys immune system attack cancer cells. The study explores if giving the drugs earlier in the day compared to later can improve treatment response and survival since time of day may impact how therapies work for some patients. Participants are randomly assigned to one of three groups receiving both drugs intravenously either in the morning 800-1100, late morning to early afternoon 1100-1400, or afternoon 1400-1700. Treatment cycles occur every 3 weeks for 4 cycles unless disease worsens or side effects occur, followed by maintenance nivolumab for up to 2 years. Patients wear an actigraphy device to monitor activity and undergo check swabs, blood tests, CT or MRI scans of the body and brain, and may optionally have tumor biopsies during the study. Throughout the study, researchers monitor progression-free survival, side effects, ability to complete treatment on schedule, tumor response, overall survival, and quality of life. After treatment ends, participants have follow-up visits every 3 months for the first year and then up to 5 years. The study also explores immune markers linked to treatment effectiveness to better understand patient outcomes.
CONDITIONS
Brief Title
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Research Team
M
Michael C. Lowe, MD, MA
Z
Zachary Buchwald, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here